- The trend backdrop is active with a 10-week active streak.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
AVTX
NASDAQ
Week ended 11 Sep 2026
Weekly Investor Report
Avalo Therapeutics Inc · Healthcare · Biotechnology
Latest close
16.12 USD
-16.2%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is -4.2% below the Trend Line and sits at 44.7% of its 52-week range. The latest completed week returned -16.2%, after a -17.7% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal; earnings are due in 48d.
Setup score
38
out of 100
Latest Close
16.12 USD
11 Sep 2026
1W Return
-16.2%
latest completed week
4W Return
-17.7%
short-term follow-through
12W Return
9.7%
quarterly tape
Trend Breadth
71.2%
37 of 52 weeks active
Volume Ratio
0.8x
vs 13-week average
- Price is below the Trend Line, which keeps downside pressure in focus.
- The share remains more than 20% below its 52-week high.
- The latest week was a sharp negative move.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-16.2%
Latest completed week; four-week move -17.7%.
Indicator stack
74/63
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Options pressure
Volatility
52/100 conviction; expected move 13.3%.
News sentiment
49/100
17 relevant articles in the latest sentiment read.
Event risk
48d
Next report is scheduled for 05 Nov 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is -4.2% below the Trend Line and sits at 44.7% of its 52-week range. The latest completed week returned -16.2%, after a -17.7% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.8x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
14 Aug
21 Aug
28 Aug
4 Sep
11 Sep
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9012-week average 0.69
12-week confirmation
Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure11/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership11/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.90Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -17.7% over four weeks, 9.7% over 12 weeks, and 51.3% over one year. The current trend has remained active for 10 consecutive weeks.
Performance by holding period
Active trend streak10 weeks
Active weeks in one year37
Trend breadth71.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.56Latest activity-pressure read.
Pressure change39.4%Four-week change in activity pressure.
Leadership-11.08Latest relative-leadership reading.
RS change-233.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 11 Sep 2026
Financial statements through 30 Jun 2026
Field coverage 79%
Model confidence 79%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength31/100Blend of value, momentum, and quality. Underlying universe rank 70; rank 1 is best.
Value41/100Relative valuation strength. Underlying universe rank 60; rank 1 is best.
Quality39/100Profitability and accounting quality. Underlying universe rank 62; rank 1 is best.
Momentum41/100Medium-term price momentum. Underlying universe rank 60; rank 1 is best.
Growth41/100Revenue and earnings growth. Underlying universe rank 60; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -8.5% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- -154844.1% Operating profit retained from revenue.
- Free-cash-flow margin
- -112505.1% Free cash flow generated from revenue.
- Return on invested capital
- -18.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -86.6% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 1/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -2.6% Net share repurchases relative to market value.
- Shareholder yield
- -2.6% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.9x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
AVTX shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 13.3%, and Sharemaestro trend signal active.
Conviction52/100
Expected move13.3%
Put/call volume0.00
Insider activity6 / 14
6 acquisitions and 14 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment49/100
Weighted news tone is neutral across 17 relevant articles.
1 positive · 7 neutral · 9 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings48dNext report is scheduled for 05 Nov 2026; event risk rises as the date approaches.
Options expected move13.3%Nearest-chain priced movement where available.
52-week drawdown-33.6%Distance below the 52-week high.
13-week volatility8.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
20 Mar
17 Apr
15 May
12 Jun
10 Jul
7 Aug
11 Sep
Weeks higher12 of 2614 weeks finished lower.
Best week+57.3%Week of 8 May.
Worst week-23.1%Week of 10 Apr.
Latest week-16.2%Week of 11 Sep.
Shape of recent returns
Strong gains6
Modest gains6
Flat weeks0
Modest losses7
Sharp losses7
Recent vol8.4%13-week weekly-return volatility.
Base vol13.3%52-week weekly-return volatility.
Up/down split25/26Count of positive and negative weeks in the 52-week window.
Average skew10.8% / -7.2%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average0.6%
Trend breadth70.0%
Trend70.0%active weekly trend signals
MD69.0%positive activity pressure
RS53.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average-0.7%
Trend breadth76.0%
Trend76.0%active weekly trend signals
MD69.0%positive activity pressure
RS61.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape44/100
Trend, activity pressure, participation, and risk combine to a 44/100 tape read.
Indicator analysis82/100Latest 12-week confirmation: trend 10/12, activity pressure 11/12, relative leadership 11/12.
Activity pressure 0.90; No reversal markers Factors37/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 89; Small Cap Core rank 62 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options35/100AVTX shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of 0.00, expected move of 13.3%, and Sharemaestro trend signal active.
Volatility · Volatility expansion watch · Expected move 13.3% Sentiment49/100Weighted news tone is neutral across 17 relevant articles.
Avalo Therapeutics at Cantor conference: building around il-1 beta By Investing.com Insiders6 / 146 acquisitions and 14 disposals in the latest 180-day insider tape.
Earnings48dNext report is scheduled for 05 Nov 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 11 Sep 2026 | 16.12 USD | -16.2% | 16.83 USD | 12.55 USD | 0.56 | -11.08 | 4.9M | On |
| 4 Sep 2026 | 19.23 USD | -1.8% | 16.76 USD | 12.65 USD | 0.60 | 5.82 | 4.3M | On |
| 28 Aug 2026 | 19.59 USD | -1.2% | 16.60 USD | 12.67 USD | 0.53 | 8.72 | 3.7M | On |
| 21 Aug 2026 | 19.83 USD | 1.2% | 16.45 USD | 12.68 USD | 0.45 | 11.45 | 4.0M | On |
| 14 Aug 2026 | 19.59 USD | 6.9% | 16.31 USD | 12.71 USD | 0.40 | 8.32 | 2.8M | On |
| 7 Aug 2026 | 18.32 USD | 0.4% | 16.16 USD | 12.77 USD | 0.60 | 3.32 | 3.8M | On |
| 31 Jul 2026 | 18.25 USD | -1.0% | 16.11 USD | 12.85 USD | 0.62 | 9.00 | 4.6M | On |
| 24 Jul 2026 | 18.44 USD | -4.8% | 16.07 USD | 13.00 USD | 0.66 | 11.82 | 3.8M | On |
| 17 Jul 2026 | 19.37 USD | 0.8% | 16.07 USD | 13.18 USD | 0.71 | 16.99 | 4.7M | On |
| 10 Jul 2026 | 19.21 USD | 2.0% | 16.04 USD | 13.51 USD | 0.45 | 12.72 | 6.2M | On |
| 3 Jul 2026 | 18.84 USD | 3.5% | 16.02 USD | 13.90 USD | 0.24 | 14.21 | 7.7M | Off |
| 26 Jun 2026 | 18.20 USD | 23.8% | 15.98 USD | 14.33 USD | -0.05 | 12.92 | 16.1M | Off |
| 19 Jun 2026 | 14.70 USD | -0.4% | 16.01 USD | 14.76 USD | -0.21 | -11.63 | 10.1M | Off |
| 12 Jun 2026 | 14.76 USD | 12.7% | 16.11 USD | 21.46 USD | -0.09 | -8.03 | 5.9M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.